Literature DB >> 29470738

Prevalence and type II diabetes-associated factors in psoriatic arthritis.

Rubén Queiro1, Andrés Lorenzo2, Estefanía Pardo2, Anahy Brandy2, Pablo Coto3, Javier Ballina2.   

Abstract

Diabetes is a common cardiovascular risk factor in psoriatic arthritis (PsA). Although the prevalence of diabetes is high, the factors associated with it in PsA are poorly understood. We aimed to analyse the prevalence of type II diabetes and diabetes-associated factors in a hospital-based population with PsA. This cross-sectional study included 340 consecutive patients attended in a tertiary care hospital. The prevalence of diabetes was compared to that of 600 outpatients without inflammatory conditions. To analyse diabetes-associated factors, odds ratio (OR) values were calculated by conditional logistic regression analysis. Significant variables in the univariate analysis were then introduced in a multivariate analysis with a backward stepwise approach. Diabetes was more prevalent among PsA patients (13.8 vs. 5%, OR 2.8, 95% CI: 1.7-4.3, p < 0.0001). Diabetes-associated factors in the univariate analysis (p < 0.05) were the following: an age of onset of psoriasis > 40 years, an age of onset of arthritis > 40 years, a low educational level, family history of psoriasis, pustular psoriasis, high number of swollen joints during follow-up, hypertension, dyslipidemia, obesity, and cardiovascular events. After controlling for several confounders, diabetes was significantly associated with late-onset psoriasis (OR 8.2, 95% CI: 1.9-12.4, p = 0.002) and hypertension (OR 7.5, 95% CI: 1.5-13.3, p = 0.008). Diabetes risk should be carefully evaluated in patients with PsA whose psoriasis begins after 40 years.

Entities:  

Keywords:  Cardiovascular risk; Diabetes; Late-onset disease; Psoriasis; Psoriatic arthritis

Mesh:

Year:  2018        PMID: 29470738     DOI: 10.1007/s10067-018-4042-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Comorbidities in Psoriatic Arthritis.

Authors:  M Elaine Husni
Journal:  Rheum Dis Clin North Am       Date:  2015-09-05       Impact factor: 2.670

Review 2.  Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.

Authors:  Francesco Caso; Antonio Del Puente; Francesca Oliviero; Rosario Peluso; Nicolò Girolimetto; Paolo Bottiglieri; Francesca Foglia; Carolina Benigno; Marco Tasso; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

3.  The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease.

Authors:  Lihi Eder; Vinod Chandran; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2013-07-25       Impact factor: 19.103

Review 4.  Lean, but not healthy: the 'metabolically obese, normal-weight' phenotype.

Authors:  Cherlyn Ding; Zhiling Chan; Faidon Magkos
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2016-11       Impact factor: 4.294

5.  Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project.

Authors:  Santos Castañeda; María A Martín-Martínez; Carlos González-Juanatey; Javier Llorca; María J García-Yébenes; Sabina Pérez-Vicente; Jesús T Sánchez-Costa; Federico Díaz-Gonzalez; Miguel A González-Gay
Journal:  Semin Arthritis Rheum       Date:  2014-12-25       Impact factor: 5.532

6.  Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris.

Authors:  T Henseler; E Christophers
Journal:  J Am Acad Dermatol       Date:  1985-09       Impact factor: 11.527

Review 7.  Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  P Coto-Segura; N Eiris-Salvado; L González-Lara; R Queiro-Silva; P Martinez-Camblor; C Maldonado-Seral; B García-García; L Palacios-García; S Gomez-Bernal; J Santos-Juanes; E Coto
Journal:  Br J Dermatol       Date:  2013-10       Impact factor: 9.302

Review 8.  Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.

Authors:  April W Armstrong; Elizabeth A Brezinski; Matthew R Follansbee; Ehrin J Armstrong
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 9.  A comprehensive review on metabolic syndrome.

Authors:  Jaspinder Kaur
Journal:  Cardiol Res Pract       Date:  2014-03-11       Impact factor: 1.866

Review 10.  Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.

Authors:  Lluís Puig
Journal:  Int J Mol Sci       Date:  2017-12-25       Impact factor: 5.923

View more
  5 in total

Review 1.  Hypertension in connective tissue disease.

Authors:  Qiang Luo; Yiwen Zhang; Xiaoqian Yang; Li Qin; Han Wang
Journal:  J Hum Hypertens       Date:  2022-05-03       Impact factor: 3.012

2.  Discrepancy in Metabolic Syndrome between Psoriatic Arthritis and Rheumatoid Arthritis: a Direct Comparison of Two Cohorts in One Center.

Authors:  Borui Li; Hong Huang; Juan Zhao; Xuerong Deng; Zhuoli Zhang
Journal:  Rheumatol Ther       Date:  2022-10-20

Review 3.  Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.

Authors:  Francesco Caso; Marco Tasso; Maria Sole Chimenti; Luca Navarini; Carlo Perricone; Nicolò Girolimetto; Rosario Peluso; Antonio Del Puente; Antonella Afeltra; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

Review 4.  Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.

Authors:  Sakir Ahmed; Armen Yuri Gasparyan; Olena Zimba
Journal:  Rheumatol Int       Date:  2021-01-03       Impact factor: 3.580

Review 5.  Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.

Authors:  Giacomo Dal Bello; Paolo Gisondi; Luca Idolazzi; Giampiero Girolomoni
Journal:  Rheumatol Ther       Date:  2020-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.